High-risk human papillomavirus (HPV) infection is known to be a necessary factor for cervical and anogenital malignancies. Cervical cancers account for over a quarter of a million deaths annually. Despite the availability of prophylactic vaccines, HPV infections remain extremely common worldwide. Furthermore, these vaccines are ineffective at clearing pre-existing infections and associated preinvasive lesions. As cervical dysplasia can regress spontaneously, a therapeutic HPV vaccine that boosts host immunity could have a significant impact on the morbidity and mortality associated with HPV. Therapeutic vaccines differ from prophylactic vaccines in that they are aimed at generating cell-mediated immunity rather than neutralising antibodies. This review will cover various therapeutic vaccine strategies in development for the treatment of HPV-associated lesions and cancers.
Journal article
2018-02-01T00:00:00+00:00
47
59 - 72
13
Bacterial vector, DNA vaccine, HPV-Associated malignancies, High-risk human papillomavirus, Therapeutic vaccine, Viral vector, Cancer Vaccines, Female, Global Health, Humans, Papillomaviridae, Papillomavirus Infections, Papillomavirus Vaccines, Uterine Cervical Neoplasms, Vaccination Coverage, Uterine Cervical Dysplasia